Brenda R. Hemmelgarn, MD, PhD
Articles
October 14th 2014
A Systematic Review of Value-Based Insurance Design in Chronic Diseases
Karen L. Tang, MD Lianne Barnieh, PhD Bikaramjit Mann, MD Fiona Clement, PhD David J.T. Campbell, MD, MSc Brenda R. Hemmelgarn, MD, PhD Marcello Tonelli, MD, SM Diane Lorenzetti, MLS Braden J. Manns, MD, MSc
Value-based insurance design for prescription drug coverage increases drug adherence in patients with chronic disease, though their effect on clinical outcomes and health spending remain uncertain.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: September 19th 2024 | Updated: November 21st 2024
Institute for Value-Based Medicine®: Speakers Use AML Studies to Illustrate Effects of Disparities, Neighborhood Stress on Outcomes
